Financial Architects (New Jersey)’s Travere Therapeutics TVTX Stock Holding History

Financial Architects (New Jersey)’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,000	Closed	-$45K	–	1507
2016 Q3	$45K	Hold	2,000	–	–	0.01%	603
2016 Q2	$36K	Hold	2,000	–	–	0.01%	627
2016 Q1	$27K	Buy	+2,000	New	+$30.3K	0.01%	522
2015 Q3	–	Sell	-2,000	Closed	-$66K	–	863
2015 Q2	$66K	Buy	+2,000	New	+$54.8K	0.02%	384
2014 Q4	–	Sell	-2,000	Closed	-$18K	–	1037
2014 Q3	$18K	Hold	2,000	–	–	0.01%	498
2014 Q2	$23K	Buy	+2,000	New	+$27.1K	0.01%	472

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Architects (New Jersey)'s TVTX Position: Q4 2016 in Review

Financial Architects (New Jersey) sold out of Travere Therapeutics (TVTX) in Q4 2016, closing a stake of 2,000 shares — an estimated $45K sold.

Financial Architects (New Jersey) first reported a position in TVTX in Q2 2014 and held it in 6 quarters. The position peaked at $66K in Q2 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

Financial Architects (New Jersey) reported no remaining Travere Therapeutics position as of Q4 2016 after selling out during the quarter.
Financial Architects (New Jersey) sold 2,000 Travere Therapeutics shares in Q4 2016, an estimated $45K.
Financial Architects (New Jersey) first reported a position in Travere Therapeutics in Q2 2014 and held it in 6 quarters.
Financial Architects (New Jersey)'s Travere Therapeutics position peaked at $66K in Q2 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2016, filed 6 Feb 2017.